Jubilant Pharmova Limited has recommended a final dividend of ₹5 per equity share for the financial year ended March 31, 2026, subject to shareholder approval at its 48th Annual General Meeting (AGM) scheduled for Wednesday, August 26, 2026. The meeting will be held via Video Conferencing (VC) or Other Audio-Visual Means (OAVM), allowing members to participate without physical presence. This dividend recommendation follows a strong FY26 performance where revenue grew 14% year-over-year to ₹82,796 Million, driven by robust demand in the CDMO Sterile Injectables segment.

The Board of Directors has fixed Friday, July 24, 2026, as the record date for determining dividend entitlements. Shareholders whose names appear in the Register of Members on this date will be eligible to receive the dividend, which aggregates to ₹796.41 Million. The dividend is taxable in the hands of shareholders pursuant to the Finance Act, 2020, effective April 1, 2020. To facilitate Tax Deducted at Source (TDS) compliance under the Income-tax Act, 1961, shareholders are required to submit relevant tax documents to investors@jubl.com on or before Friday, August 14, 2026. Failure to update bank details with Depository Participants or the Registrar and Transfer Agent, Alankit Assignments Limited, may delay dividend payments.

E-Voting Schedule and Procedures

Shareholders can cast their votes electronically through the National Securities Depository Limited (NSDL) platform. The e-voting process adheres to Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The cut-off date for determining voting rights is Wednesday, August 19, 2026. Only members holding shares as of this date will be eligible to vote.

The following table outlines the critical dates for the AGM and e-voting process:

Members who have already voted via remote e-voting can attend the AGM but cannot vote again. Those who have not voted remotely can exercise their voting rights during the meeting via VC/OAVM. Once a vote is cast, it cannot be modified. Shareholders without registered email addresses should update their details using Form ISR-1 with Alankit Assignments Limited or their respective Depository Participants.

FY26 Financial Highlights

The dividend recommendation is supported by solid operational growth in FY26. Total revenue from operations rose to ₹82,796 Million from ₹72,345 Million in FY25. The CDMO Sterile Injectables segment was a key driver, with revenue surging 38% to ₹17,548 Million, aided by commercial technology transfers from the Spokane facility’s Line 3. Radiopharma revenue also grew 9% to ₹36,901 Million.

While reported Profit After Tax (PAT) declined to ₹3,975 Million from ₹8,363 Million due to exceptional items, Normalised PAT increased 7% to ₹4,424 Million, reflecting improved core operating performance. EBITDA stood at ₹13,255 Million with a margin of 16%, compared to 17% in the previous year. The company continues to track towards its Vision 2030 targets, including doubling revenues from the FY24 baseline and achieving zero net debt.

Director Re-appointments

The AGM will also consider the re-appointment of two directors retiring by rotation: Mr. Hari Shanker Bhartia, Co-Chairman, and Mr. Arjun Shanker Bhartia, Joint Managing Director. Both directors attended all six Board meetings held during FY26. Mr. Hari Shanker Bhartia, a Chemical Engineering graduate from IIT Delhi, has served on the Board since November 1, 1983. Mr. Arjun Shanker Bhartia, who joined the Board in May 2017, has been Joint Managing Director since June 2023.

Jubilant Pharmova Limited has notified shareholders of an August 14, 2026, deadline to submit tax documentation for its proposed final dividend of ₹5 per equity share. The communication, issued on August 1, 2026, outlines withholding tax rates and exemption procedures under the Income-tax Act, 2025, ensuring investors can optimize their tax liability before the record date of July 24, 2026. This procedural update follows the Board’s recommendation of the dividend on May 22, 2026, subject to approval at the Annual General Meeting (AGM) scheduled for August 26, 2026.

Dividend Taxation and Submission Deadlines

The company will deduct tax at source (TDS) based on shareholder category and residential status unless valid exemptions are claimed. Shareholders must submit requisite forms and declarations to Alankit Assignments Limited or their Depository Participants by August 14, 2026. Documents received after this date will not be considered for lower or nil tax deduction.

For resident individuals, no tax will be deducted if the total dividend received in FY 2026-27 does not exceed ₹10,000. However, if PAN is not registered or linked with Aadhaar, TDS will be applied at a higher rate of 20% under Section 397(2) of the Income-tax Act, 2025, regardless of the dividend amount. Non-resident shareholders seeking treaty benefits must provide a Tax Residency Certificate, e-filed Form 41, and a self-declaration confirming no permanent establishment in India.

AGM and Financial Context

The dividend recommendation is part of the business transacted at the 48th AGM on August 26, 2026. The meeting will also adopt audited financial statements for FY 2025-26, where Jubilant Pharmova reported revenue from operations of ₹82,796 million, a 14% increase year-on-year. Normalised Profit After Tax (PAT) rose 7% to ₹4,424 million. The proposed dividend aggregates to ₹796.41 million.

Shareholders holding shares in dematerialized mode are advised to update KYC details, including PAN and bank accounts, with their Depository Participants. Those holding physical shares must coordinate directly with the company or its Registrar and Transfer Agent. The company reserves the right to verify PAN status independently and apply higher withholding rates if discrepancies are found.

Key Dates for Shareholders

Investors are urged to consult tax advisors as the communication does not constitute exhaustive tax advice. The company will issue TDS certificates via email post-filing of returns, allowing shareholders to download Form 168 from the Income Tax Department’s portal.